We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2015 by Xu Zhang, Taixing People's Hospital.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01561222
First Posted: March 22, 2012
Last Update Posted: June 8, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Xu Zhang, Taixing People's Hospital
  Purpose
Vitamin D Supplement in patients with CKD stage 1 and 2 may change osteoprotegin expression so as to produce beneficial effects of cardiovascular、bone metabolism and CKD progression.

Condition Intervention Phase
Chronic Kidney Disease Stage 1 Chronic Kidney Disease Stage 2 Drug: Calcitriol Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention

Resource links provided by NLM:


Further study details as provided by Xu Zhang, Taixing People's Hospital:

Primary Outcome Measures:
  • Osteoprotegin level [ Time Frame: one year ]
    To assess the effect of vitamin D supplementation on osteoprotegin level in CKD patients


Secondary Outcome Measures:
  • Bone mineral density [ Time Frame: one year ]
    To assess the effect of vitamin D supplementation on bone mineral density in patients with CKD stage 1 and 2

  • vascular calcification score [ Time Frame: one year ]
    To assess the effect of vitamin D supplementation on vascular calcification score through performing lateral abdominal radiography or CT-based techniques in patients with CKD stage 1 and 2


Estimated Enrollment: 300
Study Start Date: July 2015
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo Drug: placebo
one pill per day
Experimental: Calcitriol Drug: Calcitriol
0.25 ug per day for one year
Other Name: Rocaltrol

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of CKD stage 1 and 2
  • Age >18 years
  • Ability to provide informed consent

Exclusion Criteria:

  • On vitamin D in past 4 weeks
  • Plans to relocate out of Taixing City in the next one year
  • Serum phosphate >5.5 mg/dl in past 3 months
  • Serum calcium >10.0 mg/dl in past 3 months
  • Cancer
  • Transplanted organ
  • Rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01561222


Contacts
Contact: Xu Zhang, Bachelor 008-613-905-266-789 dr.zhangxu@tom.com
Contact: Cai-xia Zhao, Master 008-615-896-079-628 zhaocaixia2010@yahoo.cn

Locations
China, Jiangsu
Taixing People's Hospital Not yet recruiting
Taixing, Jiangsu, China, 225400
Contact: Xu Zhang, bachelor    008-613-905-266-789    dr.zhangxu@tom.com   
Sponsors and Collaborators
Taixing People's Hospital
  More Information

Responsible Party: Xu Zhang, Zhang Xu, Taixing People's Hospital
ClinicalTrials.gov Identifier: NCT01561222     History of Changes
Other Study ID Numbers: zhangxu2012
First Submitted: March 19, 2012
First Posted: March 22, 2012
Last Update Posted: June 8, 2015
Last Verified: June 2015

Keywords provided by Xu Zhang, Taixing People's Hospital:
calcitrol
Bone mineral density
Osteoprotegin
Vascular calcification

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Calcitriol
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents